Guillemette Beaudonnet

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy

Pierre Lozeron, Louise‐Laure Mariani, Pauline Dodet et al. · Neurology · 2018 · 94 citations

Medicine, Neurology, Neuroscience +17

Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis

Guilhem Solé, Stéphane Mathis, Diane Friedman et al. · Neurology · 2021 · 57 citations

Medicine, Infectious Diseases, Internal Medicine +13

Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis

Luca Leonardi, Clovis Adam, Guillemette Beaudonnet et al. · European Journal of Neurology · 2022 · 47 citations

Medicine, Dermatology, Neurology +17

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae

Léo Plaçais, Jean‐Marie Michot, Stéphane Champiat et al. · Brain Communications · 2021 · 46 citations · Full text

Medicine, Neurology, Oncology +17